Status:
COMPLETED
Depot-medroxyprogesterone Acetate (DMPA) Contraceptive Method and Metabolism
Lead Sponsor:
University of Campinas, Brazil
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Insulin Resistance
Cardiovascular Disease
Eligibility:
FEMALE
18-40 years
Brief Summary
Objective: The purpose of this study is to determine the etiology of the weight increase in Depot-medroxyprogesterone Acetate (DMPA) users. Method: Prospective study with 100 women, aged 18-40 year...
Eligibility Criteria
Inclusion
- 18-40 years
- new users of DMPA
- BMI\<30kg/m²
Exclusion
- diabetes mellitus and 2 present or fasting glucose\> 100mg/dl and / or blood glucose\> 140mg/dl after ingestion of 75mg of oral glucose
- first-degree relatives with diabetes mellitus
- period of lactation
- hypertension, with or without treatment
- hyper and hypothyroidism
- chronic renal failure
- transplant of any organ
- women using drugs that may be related to weight gain and / or development of insulin resistance and chronic use of corticosteroids, antipsychotics, statins, and thiazide,
- hirsutism and/or hyperandrogenism
- polycystic Ovary Syndrome (PCOS)
- women with acanthosis nigricans
- women who have used depoprovera at some point in their reproductive lives,
- women who have performed bariatric surgery
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01527526
Start Date
February 1 2011
End Date
February 1 2013
Last Update
June 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Campinas
Campinas, São Paulo, Brazil, 13083-888